Following a primaryscreening in cancer stem cells (CSCs), we have identified the syntheticcompound UCM-13369 that has been subsequently characterized as a nucleophosmin1 (NPM1) inhibitor that specifically recognizes the C-end DNA-bindingdomain of the protein. Here, NPM1 is linked to cancer.